Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
BOTHELL, Wash., April 06, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering of 5,376,344 shares of its common stock at a price to the public of $23.25 per share. In addition, Alder has granted the underwriters a 30-day option to purchase up to 806,451 additional shares of common stock at the public offering price. The offering is expected to close on April 12, 2016, subject to customary closing conditions.
J.P. Morgan Securities LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was effective on filing on June 2, 2015. A preliminary prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525 ext. 6142, or by email at [email protected]; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by phone at 1-800-326-5897, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contacts: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected]
